Background: Collagenase clostridium histolyticum (CCH) injection is an established alternative to surgical fasciectomy in selected patients with Dupuytren's contracture. Collagenase is currently not listed on the Pharmaceutical Benefits Scheme creating a barrier to its use in the Australian public health system. This study compares the cost of CCH delivered in an outpatient setting with a comparable surgical fasciectomy cohort, calculated retrospectively.
for surgery) and a higher recurrence rate. [2] [3] [4] Therefore, a public hospital offering the treatment has to bear the cost of the injection. As there is no specific diagnosis related group (DRG) code for chemical fasciectomy, there is no defined process for reimbursement of the activity performed at an outpatient service. Although this would seemingly be more cost-effective, it is unclear who bears the cost of the injection, as it is a medical treatment for a surgical condition.
The purpose of this paper is to compare the cost of CCH treatment in an outpatient setting in the Australian public system with single-digit fasciectomy.
Methods
We conducted a retrospective audit of hospital data to calculate the cost of surgical fasciectomy. The pathway for patients undergoing CCH treatment was an initial surgical consultation, a clinic visit for the injection, a subsequent visit for joint manipulation and two outpatient reviews at one and three months respectively.
The hand therapy protocol was one initial consult for documentation of contracture severity and objective measurements followed by a visit immediately after manipulation for splinting and two subsequent visits for splint adjustment and finger motion exercises. 
Results
We identified 38 patients who underwent singledigit fasciectomy during the review period. The actual total cost per patient was calculated and compared to CCH treatment ( to CCH treatment in the short-and medium-term. 7 Zhou et al's study showed that CCH was not significantly different from fasciectomy in reducing MCP joint contractures, whereas PIP joint contractures showed slightly better reduction following limited fasciectomy. 8 As far as long-term outcome is concerned, Peimer et al's five-year Our study design has some weaknesses. The surgical group cost was calculated retrospectively and while we only calculated costs related to single-finger contracture, the severity of disease in the two cohorts may not be the same. It is also possible that there is an inherent bias in selecting patients with milder forms of contracture for CCH treatment. Nevertheless, the injection costs are lower than surgery. Additionally, we only report on the immediate outcome of the injection and have not reported on efficacy in the medium-to longterm.
In conclusion, our study highlights the substantially lower total cost of CCH injection for management 
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